In addition, you must meet one of the three clinical criteria set by CMS, measured at the time you start GLP-1 therapy: BMI of 35 or higher (and age 18 or older), or BMI of 30 or higher (and age 18 or older), plus one of the following: heart failure with preserved ejection fraction, uncontrolled high blood pressure (systolic above 140 or diastolic above 90 despite treatment with two blood pressure medications), or chronic kidney disease stage 3a or above, or BMI of 27 or higher (and age 18 or older), plus one of the following: prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease If you take a GLP-1 for another condition, the Bridge is not for you
Tagler D, Makanji Y, Tu T, Bernabe BP, Lee R, Zhu J, et al
Just like any other prescription medication, both Ozempic and metformin have their own drug interactions and potential warnings
Collectively, these data reveal that exendin 2029 acts as a key sequence in inducing analgesia in CAP-elicited nociceptive behaviors in mice without causing hyperthermia, and this analgesic effect is mediated by exendin 2029 directly inhibiting CAP-induced TRPV1 activation but not proton-induced TRPV1 activation
